The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Gestational Diabetes Treatment-Global Market Insights and Sales Trends 2024
Synopsis
Gestational diabetes can be defined as a type of diabetes that affects pregnant women. It is usually a temporary condition which develops during pregnancy and subsides after the birth of the baby. However, there are possibilities that diabetes may return in the later stages of life as type II diabetes mellitus. It is the inability of insulin to absorb the sugars consumed as part of the meal. It may be caused due to insulin resistance in a woman s body because of increasing levels of placental hormones being produced to sustain the development of the fetus. This condition starts when the female body is not able to make and use required amounts of insulin needed in pregnancy, resulting in a build-up of sugar in the bloodstream causing hyperglycemia.
The global Gestational Diabetes Treatment market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Gestational Diabetes Treatment in various end use industries. The expanding demands from the Hospital Pharmacies, Retail Pharmacies and Online Pharmacies,, are propelling Gestational Diabetes Treatment market. Insulin, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the SGLT-2 Inhibitors segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Gestational Diabetes Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Gestational Diabetes Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Gestational Diabetes Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Gestational Diabetes Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Gestational Diabetes Treatment covered in this report include Biocon Limited, Eli Lilly, Novo Nordisk, Boehringer Ingelheim GmbH, Sanofi S.A., Sun Pharmaceutical Industries Limited, Merck, Novartis and Adocia, etc.
The global Gestational Diabetes Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Biocon Limited
Eli Lilly
Novo Nordisk
Boehringer Ingelheim GmbH
Sanofi S.A.
Sun Pharmaceutical Industries Limited
Merck
Novartis
Adocia
Peptron
AstraZeneca plc
Pfizer, Inc
Takeda Pharmaceutical Company Ltd
Abbott
Antares Pharma
INJEX Pharma AG
Daiichi Sankyo
Global Gestational Diabetes Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Gestational Diabetes Treatment market, Segment by Type:
Insulin
SGLT-2 Inhibitors
Alpha-glucosidase Inhibitors
Others
Global Gestational Diabetes Treatment market, by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Gestational Diabetes Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Gestational diabetes can be defined as a type of diabetes that affects pregnant women. It is usually a temporary condition which develops during pregnancy and subsides after the birth of the baby. However, there are possibilities that diabetes may return in the later stages of life as type II diabetes mellitus. It is the inability of insulin to absorb the sugars consumed as part of the meal. It may be caused due to insulin resistance in a woman s body because of increasing levels of placental hormones being produced to sustain the development of the fetus. This condition starts when the female body is not able to make and use required amounts of insulin needed in pregnancy, resulting in a build-up of sugar in the bloodstream causing hyperglycemia.
The global Gestational Diabetes Treatment market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Gestational Diabetes Treatment in various end use industries. The expanding demands from the Hospital Pharmacies, Retail Pharmacies and Online Pharmacies,, are propelling Gestational Diabetes Treatment market. Insulin, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the SGLT-2 Inhibitors segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Gestational Diabetes Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Gestational Diabetes Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Gestational Diabetes Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Gestational Diabetes Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Gestational Diabetes Treatment covered in this report include Biocon Limited, Eli Lilly, Novo Nordisk, Boehringer Ingelheim GmbH, Sanofi S.A., Sun Pharmaceutical Industries Limited, Merck, Novartis and Adocia, etc.
The global Gestational Diabetes Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Biocon Limited
Eli Lilly
Novo Nordisk
Boehringer Ingelheim GmbH
Sanofi S.A.
Sun Pharmaceutical Industries Limited
Merck
Novartis
Adocia
Peptron
AstraZeneca plc
Pfizer, Inc
Takeda Pharmaceutical Company Ltd
Abbott
Antares Pharma
INJEX Pharma AG
Daiichi Sankyo
Global Gestational Diabetes Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Gestational Diabetes Treatment market, Segment by Type:
Insulin
SGLT-2 Inhibitors
Alpha-glucosidase Inhibitors
Others
Global Gestational Diabetes Treatment market, by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Gestational Diabetes Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Gestational Diabetes Treatment
1.1 Gestational Diabetes Treatment Market Overview
1.1.1 Gestational Diabetes Treatment Product Scope
1.1.2 Gestational Diabetes Treatment Market Status and Outlook
1.2 Global Gestational Diabetes Treatment Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Gestational Diabetes Treatment Market Size by Region (2018-2029)
1.4 Global Gestational Diabetes Treatment Historic Market Size by Region (2018-2023)
1.5 Global Gestational Diabetes Treatment Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Gestational Diabetes Treatment Market Size (2018-2029)
1.6.1 North America Gestational Diabetes Treatment Market Size (2018-2029)
1.6.2 Europe Gestational Diabetes Treatment Market Size (2018-2029)
1.6.3 Asia-Pacific Gestational Diabetes Treatment Market Size (2018-2029)
1.6.4 Latin America Gestational Diabetes Treatment Market Size (2018-2029)
1.6.5 Middle East & Africa Gestational Diabetes Treatment Market Size (2018-2029)
2 Gestational Diabetes Treatment Market by Type
2.1 Introduction
2.1.1 Insulin
2.1.2 SGLT-2 Inhibitors
2.1.3 Alpha-glucosidase Inhibitors
2.1.4 Others
2.2 Global Gestational Diabetes Treatment Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Gestational Diabetes Treatment Historic Market Size by Type (2018-2023)
2.2.2 Global Gestational Diabetes Treatment Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Gestational Diabetes Treatment Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Gestational Diabetes Treatment Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Gestational Diabetes Treatment Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Gestational Diabetes Treatment Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Gestational Diabetes Treatment Revenue Breakdown by Type (2018-2029)
3 Gestational Diabetes Treatment Market Overview by Application
3.1 Introduction
3.1.1 Hospital Pharmacies
3.1.2 Retail Pharmacies
3.1.3 Online Pharmacies
3.2 Global Gestational Diabetes Treatment Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Gestational Diabetes Treatment Historic Market Size by Application (2018-2023)
3.2.2 Global Gestational Diabetes Treatment Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Gestational Diabetes Treatment Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Gestational Diabetes Treatment Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Gestational Diabetes Treatment Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Gestational Diabetes Treatment Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Gestational Diabetes Treatment Revenue Breakdown by Application (2018-2029)
4 Gestational Diabetes Treatment Competition Analysis by Players
4.1 Global Gestational Diabetes Treatment Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Gestational Diabetes Treatment as of 2022)
4.3 Date of Key Players Enter into Gestational Diabetes Treatment Market
4.4 Global Top Players Gestational Diabetes Treatment Headquarters and Area Served
4.5 Key Players Gestational Diabetes Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Gestational Diabetes Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Biocon Limited
5.1.1 Biocon Limited Profile
5.1.2 Biocon Limited Main Business
5.1.3 Biocon Limited Gestational Diabetes Treatment Products, Services and Solutions
5.1.4 Biocon Limited Gestational Diabetes Treatment Revenue (US$ Million) & (2018-2023)
5.1.5 Biocon Limited Recent Developments
5.2 Eli Lilly
5.2.1 Eli Lilly Profile
5.2.2 Eli Lilly Main Business
5.2.3 Eli Lilly Gestational Diabetes Treatment Products, Services and Solutions
5.2.4 Eli Lilly Gestational Diabetes Treatment Revenue (US$ Million) & (2018-2023)
5.2.5 Eli Lilly Recent Developments
5.3 Novo Nordisk
5.3.1 Novo Nordisk Profile
5.3.2 Novo Nordisk Main Business
5.3.3 Novo Nordisk Gestational Diabetes Treatment Products, Services and Solutions
5.3.4 Novo Nordisk Gestational Diabetes Treatment Revenue (US$ Million) & (2018-2023)
5.3.5 Boehringer Ingelheim GmbH Recent Developments
5.4 Boehringer Ingelheim GmbH
5.4.1 Boehringer Ingelheim GmbH Profile
5.4.2 Boehringer Ingelheim GmbH Main Business
5.4.3 Boehringer Ingelheim GmbH Gestational Diabetes Treatment Products, Services and Solutions
5.4.4 Boehringer Ingelheim GmbH Gestational Diabetes Treatment Revenue (US$ Million) & (2018-2023)
5.4.5 Boehringer Ingelheim GmbH Recent Developments
5.5 Sanofi S.A.
5.5.1 Sanofi S.A. Profile
5.5.2 Sanofi S.A. Main Business
5.5.3 Sanofi S.A. Gestational Diabetes Treatment Products, Services and Solutions
5.5.4 Sanofi S.A. Gestational Diabetes Treatment Revenue (US$ Million) & (2018-2023)
5.5.5 Sanofi S.A. Recent Developments
5.6 Sun Pharmaceutical Industries Limited
5.6.1 Sun Pharmaceutical Industries Limited Profile
5.6.2 Sun Pharmaceutical Industries Limited Main Business
5.6.3 Sun Pharmaceutical Industries Limited Gestational Diabetes Treatment Products, Services and Solutions
5.6.4 Sun Pharmaceutical Industries Limited Gestational Diabetes Treatment Revenue (US$ Million) & (2018-2023)
5.6.5 Sun Pharmaceutical Industries Limited Recent Developments
5.7 Merck
5.7.1 Merck Profile
5.7.2 Merck Main Business
5.7.3 Merck Gestational Diabetes Treatment Products, Services and Solutions
5.7.4 Merck Gestational Diabetes Treatment Revenue (US$ Million) & (2018-2023)
5.7.5 Merck Recent Developments
5.8 Novartis
5.8.1 Novartis Profile
5.8.2 Novartis Main Business
5.8.3 Novartis Gestational Diabetes Treatment Products, Services and Solutions
5.8.4 Novartis Gestational Diabetes Treatment Revenue (US$ Million) & (2018-2023)
5.8.5 Novartis Recent Developments
5.9 Adocia
5.9.1 Adocia Profile
5.9.2 Adocia Main Business
5.9.3 Adocia Gestational Diabetes Treatment Products, Services and Solutions
5.9.4 Adocia Gestational Diabetes Treatment Revenue (US$ Million) & (2018-2023)
5.9.5 Adocia Recent Developments
5.10 Peptron
5.10.1 Peptron Profile
5.10.2 Peptron Main Business
5.10.3 Peptron Gestational Diabetes Treatment Products, Services and Solutions
5.10.4 Peptron Gestational Diabetes Treatment Revenue (US$ Million) & (2018-2023)
5.10.5 Peptron Recent Developments
5.11 AstraZeneca plc
5.11.1 AstraZeneca plc Profile
5.11.2 AstraZeneca plc Main Business
5.11.3 AstraZeneca plc Gestational Diabetes Treatment Products, Services and Solutions
5.11.4 AstraZeneca plc Gestational Diabetes Treatment Revenue (US$ Million) & (2018-2023)
5.11.5 AstraZeneca plc Recent Developments
5.12 Pfizer, Inc
5.12.1 Pfizer, Inc Profile
5.12.2 Pfizer, Inc Main Business
5.12.3 Pfizer, Inc Gestational Diabetes Treatment Products, Services and Solutions
5.12.4 Pfizer, Inc Gestational Diabetes Treatment Revenue (US$ Million) & (2018-2023)
5.12.5 Pfizer, Inc Recent Developments
5.13 Takeda Pharmaceutical Company Ltd
5.13.1 Takeda Pharmaceutical Company Ltd Profile
5.13.2 Takeda Pharmaceutical Company Ltd Main Business
5.13.3 Takeda Pharmaceutical Company Ltd Gestational Diabetes Treatment Products, Services and Solutions
5.13.4 Takeda Pharmaceutical Company Ltd Gestational Diabetes Treatment Revenue (US$ Million) & (2018-2023)
5.13.5 Takeda Pharmaceutical Company Ltd Recent Developments
5.14 Abbott
5.14.1 Abbott Profile
5.14.2 Abbott Main Business
5.14.3 Abbott Gestational Diabetes Treatment Products, Services and Solutions
5.14.4 Abbott Gestational Diabetes Treatment Revenue (US$ Million) & (2018-2023)
5.14.5 Abbott Recent Developments
5.15 Antares Pharma
5.15.1 Antares Pharma Profile
5.15.2 Antares Pharma Main Business
5.15.3 Antares Pharma Gestational Diabetes Treatment Products, Services and Solutions
5.15.4 Antares Pharma Gestational Diabetes Treatment Revenue (US$ Million) & (2018-2023)
5.15.5 Antares Pharma Recent Developments
5.16 INJEX Pharma AG
5.16.1 INJEX Pharma AG Profile
5.16.2 INJEX Pharma AG Main Business
5.16.3 INJEX Pharma AG Gestational Diabetes Treatment Products, Services and Solutions
5.16.4 INJEX Pharma AG Gestational Diabetes Treatment Revenue (US$ Million) & (2018-2023)
5.16.5 INJEX Pharma AG Recent Developments
5.17 Daiichi Sankyo
5.17.1 Daiichi Sankyo Profile
5.17.2 Daiichi Sankyo Main Business
5.17.3 Daiichi Sankyo Gestational Diabetes Treatment Products, Services and Solutions
5.17.4 Daiichi Sankyo Gestational Diabetes Treatment Revenue (US$ Million) & (2018-2023)
5.17.5 Daiichi Sankyo Recent Developments
6 North America
6.1 North America Gestational Diabetes Treatment Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Gestational Diabetes Treatment Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Gestational Diabetes Treatment Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Gestational Diabetes Treatment Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Gestational Diabetes Treatment Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Gestational Diabetes Treatment Market Dynamics
11.1 Gestational Diabetes Treatment Industry Trends
11.2 Gestational Diabetes Treatment Market Drivers
11.3 Gestational Diabetes Treatment Market Challenges
11.4 Gestational Diabetes Treatment Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
